Abstract: Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptidebased vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past. preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.
Immunological Challenges for Peptide-based

Immunotherapy in Glioblastoma
represented by dendritic cells (DCs) which can take up tumor-associated proteins and/or peptides and, after intracellular processing, present them via HLA class I and -II molecules on their surface. 19 Although there is some cross-talk between these two processing and presentation pathways, presentation via HLA class I will mainly prime CD8+ CTL, while peptide binding to HLA class II will induce a CD4+ T helper cell response. 20 This means, in order to mount an efficient tumor-specific immune response, both CTL as well as T helper cell activation against tumor antigens that are presented in the context of HLA-class I and -class respectively are required ( Figure 1 ).
As we would like to focus on immunological challenges that are relevant to improve immunotherapeutic protocols in a clinical setting, we will not introduce all molecules and cell populations, for example NK-and NK-T-cells, that are additionally involved in the complex interaction between immune-and cancer cells, but focus on the adaptive T cell-mediated and tumor specific immune responses.
Peptide-based immunotherapeutic approaches
Tumor vaccination protocols can either be based on vaccination with a peptide or protein, ideally one that is specific and relevant for the respective tumor. Different protocols using tumor-specific peptide antigens have been established. Crude peptide digests of the autologous tumor can be used for vaccination, but in most cases synthetically manufactured peptides are injected subcutaneously or intranodally to prime the host immune system and to expand existing tumor-specific CTL. 21 Theoretically, if the immune response is strong enough and sufficient numbers of tumor-specific CD8+ T cells expand, cell-mediated lysis of the tumor cells could lead to tumor regression, 22 and a cure is at least a possibility. Another immunotherapeutic approach is the adoptive transfer of autologous or genetically engineered tumor-specific T cell populations. Although adoptive T cell transfer harbors great potential, we will focus here on the more clinically feasible peptide-based immunotherapeutic approaches.
Another approach of inducing a tumor-specific immune reaction is dendritic cell The in vivo response rate has been particularly low in high-grade gliomas and resistance towards an immune-mediated tumor regression is a hallmark of glioblastoma. 27 It appears that not only the initiation, but also the execution of tumor-directed effector functions poses considerable obstacles in the treatment of glioblastoma. To achieve clinical success, several factors like efficient T cell activation, selection of the best antigens and peptides, immunogenic presentation as well as ways to overcome glioblastoma-associated immune evasion mechanisms or immunosuppression, have to be considered. Considering the sobering results of clinical trials, but also the at least theoretically promising advances in tumor immunology we decided to review and critically discuss immunological aspects of vaccination strategies to treat glioblastoma.
Promising data from clinical studies
It has been shown for other malignancies that peptide-based immunotherapy is able to mount a safe and effective immune response. In a randomized phase 3 trial enrolling 185 patients with advanced melanoma, the vaccine, consisting of the HLA*A02:01-restricted peptide gp100:209-217(210M) plus incomplete Freund`s adjuvant, was administered followed by interleukin-2 and compared to interleukin-2 alone. The vaccine group had a significantly higher response rate, as well as longer progression-free survival than the control group, which received the cytokine alone. 28 A therapeutic vaccine for HLA-A*02+ renal cell cancer patients consisting of multiple tumor-associated peptides was safe and already showed improved disease control in a phase 1 trial. Immunomodulation using single-dose cyclophosphamide with the aim of purging regulatory T cells that prevent efficient tumorspecific immune activation has been linked to prolonged survival among those patients, who mounted a specific immune response to the vaccine. 29 As the first trial advancing to phase III testing, peptide-vaccination targeting the epidermal growth factor receptor (EGFR) mutation III (vIII) is currently one of the most prominent examples for immunotherapy for glioblastoma. 30, 31 The preceding EGFRvIII trial results can offer important insights into in vivo dynamics of a peptide vaccine, which we would like to discuss briefly from an immunological perspective. In general, the EGFR is a tyrosine kinase overexpressed in up to 50% of tumors. 32 The EGFRvIII is a mutated form of this receptor, harboring a constant deletion within the extracellular domain. The peptide used in the EGFRvIII trials spans this mutated EGFR region, thereby displaying a tumor-specific neoantigen for T cell-mediated immunotherapy that is not expressed in normal tissue.
Although this mutation is present in up to 20% of high-grade gliomas, the high tumor heterogeneity results in a large proportion of cells (24-63%), which do not express this antigen. 30, 33 A phase II trial, named ACTIVATE, applied the classical peptide vaccination protocol.
The treatment regimen consisted of surgical tumor resection (gross total resection > 95%)
followed by radiotherapy combined with temozolomide treatment. After completion of chemotherapy the patients had to be progression free for 4 weeks before being vaccinated with the peptide. The 14-amino-acid long, EGFRvIII peptide was administered subcutaneously every two weeks together with an immune booster (GM-CSF). Patients were monitored every two months with MRI. If radiographic progression was detected, therapy was discontinued. Results demonstrated prolonged progression free survival and mean overall survival of vaccinated patients compared to a historically matched cohort. 34, 35 Clinical efficacy of the EGFRvIII peptide vaccination will be further assessed in an international multicenter randomized double blind placebo controlled trial called ACT IV.
So far, the EGFRvIII trials generated two immunologically interesting results relevant for future glioma vaccinations. First, patients, in whom an EGFRvIII-specific antibody response was detected, had a significantly prolonged overall survival raising the interesting point that not only T cell-mediated, but also humoral, i. With a great variety of clinical trials using immunotherapy for cancer, additional interesting data can be expected in the near future. Table 1 summarizes ten ongoing clinical trials using peptide-based vaccination to apply immunotherapy to glioblastoma.
IMMUNOLOGICAL CHALLENGES OF GLIOBLASTOMA
Immunotherapy can be successful because not only in vitro but also in vivo studies have shown that it is possible to induce a tumor-specific immune response. Glioblastoma patients exhibit significant in vivo frequencies of tumor-specific T cells without prior stimulation via a vaccinating agent. 36 Experiments using murine models demonstrated that long-term immunity and effective tumor rejection can be stimulated by vaccination. 37 Additional data dissecting human glioblastoma tissue phenotypes further discovered a correlation between the magnitude of CD8+ T cell infiltration and a prolonged overall survival. 38, 39 Such data provides evidence of the immune system`s ability to limit tumor progression. Unfortunately, until today clinical trials have not been able to translate these findings into clinical success. Since increasing evidence suggests the presence of a complex tumor-host interaction, we will review the immunological aspects of glioblastoma pathophysiology in the following sections.
Tumor evasion and immunosuppression
Malignant tumors are often depicted as a homogeneous cell population, which is characterized by uncontrolled cell growth. This view has changed over the past decades. 40 Tumors, and especially malignant gliomas, have been shown to interfere not only with the surrounding tissue, e.g. activating angiogenesis, but also to interact with the immune system. 27 Although the brain is conventionally considered an immunoprivileged organ, immune cells constantly cross the blood brain barrier, albeit to a lesser extent compared to other organs like skin or gut. Since the immune system is able to identify malignant cells in the early stages of tumor formation in a process called cancer immunosurveillance, 14 initial mutations in the cancerogenesis of glioblastoma most likely confer characteristics that help to evade or suppress the immune system or, alternatively, are not "seen" by immune cells in a sufficiently immunogenic context to mount an efficient tumor response. This indicates that the immune system may present as a selection-factor in tumor development, also described by the term immunoediting in analogy to immune receptor editing. 41 Tumor evasion is generally thought to be due to low expression of immunogenic target antigens by tumor cells, rendering them "poorly visible" for T cells, while immunosuppression is defined by multiple mechanisms that inhibit adaptive anti-tumor immune responses. 27, 42 Only malignant cells that have gained the ability to suppress and/or evade the immune system survive and evolve to a progressing malignancy. Further, driven by cancer stem-or glioma-initiating cells (GSC) the tumor continuously de-differentiates, differentiates and renews itself, with the result of compromising the immune system`s ability to identify and distinguish malignant from normal brain tissue.
Studies investigating glioblastoma tissue composition revealed that up to 3.2% of cells within a tumor express the pan T cell marker CD3, demonstrating the local presence of immune effector cells. 43 Although a remarkable amount of tumor-infiltrating lymphocytes (TIL) seems to be tumor-antigen specific, most of them do not execute any effector functions or contribute to tumor regression -they virtually have been rendered silent. [44] [45] [46] Especially, highgrade gliomas have been shown to suppress, modulate and evade the immune system at multiple levels. 27, 41 Hereby the tumor not only alters its immunological appearance, but also plays an active role by manipulating the immune system in its favor.
In the local tumor environment, soluble factors like prostaglandine E 2 (PGE 2 ), transforming growth factor beta (TGF-) and interleukin-10 (IL-10) have been described to affect immune function. 44, 47, 48 PGE 2 inhibits T cell activation, suppresses NK cell activity, downregulates HLA class II expression and induces upregulation of FoxP3 and production of IL-10 in non-T reg cells, steering immune cell composition towards a T reg phenotype. [49] [50] [51] TGF- inhibits T cell proliferation, activation and the function of cytotoxic molecules like perforin or granzymes. 51 In addition, TGF- impedes DC maturation and antigen presentation, working synergistically with IL-10 in preventing T cell activation and IL-2-induced proliferation. 52, 53 TGF- is partly controlled by adhesion molecule signaling. Integrins like αv, β3 or β5 have been found to control the TGF- pathway in glioblastoma. 47 Moreover, these soluble factors can be produced by the glioma cells themselves or by local immune cells. 27 As mentioned above, immune cell infiltration represents a strong feature of gliomas.
Almost 25% of all tumor-infiltrating lymphocytes express the regulatory T cell markers CD4, CD25 and FoxP3. 54 Interestingly, the infiltration of CD4+ CD25+ regulatory T cells correlates with glioma malignancy grade, 55 suggesting that malignant progression is closely associated with increased attraction of regulatory T cells. The increased recruitment directly correlates with a negative impact on survival. 42 The suppression of anti-tumor immune responses, however, is not only restricted to the local tumor environment but also appears to extend to a systemic level, since tumor-specific regulatory T cells were also found to be elevated in peripheral blood of glioma patients. 56, 57 As a consequence an impaired CD4+ T cell proliferation was observed due to the increased fraction of T regs in glioblastoma. 58, 59 Along with active immunosuppression, glioblastoma mechanisms evolved to evade and counteract CTL-mediated lysis. As mentioned above, a tumor-specific T cell can only identify the tumor if it recognizes tumor antigen bound to surface HLA class I. Mutations within the peptide processing machinery such as altered peptide cleavage or loss of TAP expression, have been described. One mechanism of the immune system to counteract tumor-associated loss of HLA class I expression is NK cell-mediated lysis. 64 NK cells expressing the killer immunoglobulinlike receptor (KIR) are activated if the HLA class I molecule is absent. 65 Recently, HLA-G has been described to bind to the inhibitory ILT2 receptor expressed by NK cells, thereby counteracting NK cell activation and CTL-based tumor lysis. HLA-G is expressed by several tumors including glioblastoma, which may contribute to protection from NK cell killing after loss of HLA class I. 66 In addition, malignant gliomas have been shown to also express HLA-E, another non-classical HLA-molecule that inhibits NKG2D-mediated tumor cell lysis. [67] [68] [69] [70] An additional mechanism to hinder immune-and cancer cell interaction is the impairment of adhesion molecule functions. For example, expression of the intercellular adhesion molecule (ICAM-1, CD54) is required for tumor rejection in vivo. 71 Since target cell lysis and T cell recognition of TAA presented by HLA class I is dependent on LFA-1/ICAM-1 interaction, the disruption of this mechanism leads to impaired T cell activation. 72, 73 Further, extracts from U251 glioma cell lines have shown that extracellular matrix proteins like tenascin-C can inhibit T cell proliferation and cytokine production. 74, 75 Glioma cells can also secret glycosaminoglycans, consequently creating a mechanical barrier for immune cell infiltration. environment can lead to T cell anergy and apoptosis, thereby impairing T cell activation in the local tumor environment. 81, 82 Together, the immunomodulatory mechanisms reviewed above primarily impair T cell activation, cytokine production and execution of effector functions. As a result, the local tumor environment counteracts an effective anti-tumor response. All peptide vaccination strategies will face the challenge of overcoming the local immunosuppression. Although well designed vaccination protocols will presumably be able to recruit large quantities of tumorspecific immune cells, a combined approach that simultaneously tackles the immunosuppressive mechanisms of glioblastoma will most likely be inevitable.
Challenges in antigen selection
Tumor-specific CTLs need to directly interact with the glioma cell to execute their tumor lysing effector functions. This cell-cell-interaction, also called immunological synapse, is mainly defined by the tumor-specific TCR and its cognate tumor-antigen:HLA complex, as well as costimulatory molecules. 83 When searching for the ideal tumor antigen for peptide vaccination, the following considerations have to be taken into account: 1) CTLs can only induce apoptosis and lyse tumor cells, if their specific antigen is naturally presented on a HLA class I molecule. 2) HLA class I molecules are highly polymorphic -different allelic variants bind different sets of peptides. 84 3) To avoid autoimmunity, the ideal antigen should be expressed exclusively on tumor tissue, or, if an autoimmune response against an antigen should develop, the respective target organ/cell should not lead to major toxicity.
The HLA molecules, which are responsible for presentation of peptides derived from TAAs, are cell surface glycoproteins consisting of an invariant β 2 -microglobulin chain and a highly polymorphic heavy chain. They are expressed on the surface of almost all nucleated cells and present peptides of eight to twelve amino acids length to T cells. 84, 85 As mentioned above, this peptide:HLA complex is the key structure of the immunological synapse and the level at which the immune system recognizes antigenic structures (see Fig 1 and 2) . Proteins For surface expression by an HLA molecule, certain amino acids at specific positions of the peptide have to bind into so called "anchoring pockets" of the HLA molecule.
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Depending on its polymorphic regions, every HLA allele requires certain amino acid combinations for their anchoring pockets. 88 If the peptide used for vaccination is not compatible with the HLA haplotype of the patient, it will not be presented to the TCR, and an immune response against the tumor cannot be primed. Most immunotherapeutic approaches in the past have focused on HLA-A*02-restricted peptides since HLA-A*02 is the most prevalent HLA-class I allele in Caucasians, 89 and therefore it has to be taken into consideration, that predominantly HLA-A*02+ patients will benefit from such approaches. By analyzing all HLA class I peptides of an individual patient, one can offer a much broader range of peptides for vaccination, hence limiting the risk of tumor escape.
Possible sources for tumor-associated antigens are differentiation and housekeeping/metabolic antigens, cancer-testis antigens, as well as mutated, differentially spliced, overexpressed or viral antigens. 90 Although the exclusive expression is not required for this approach to work, it certainly reduces the risk of autoimmune reactions. When peptide vaccines derived from overexpressed self-antigens are employed, it appears that the anti-tumor effect correlates with the rate of autoimmunity. 91 For instance, vitiligo is a wellknown phenomenon in the immune response to melanoma and is due to shared melanocyte/melanoma antigens -meaning that antigens are presented on both, the healthy melanocyte and the dedifferentiated melanoma cell. 92, 93 In the setting of melanoma immunotherapy, the rate of autoimmunity correlates with cancer regression and this side effect occurs in a non-essential organ. Thus, vitiligo poses only a relative concern when being confronted with a life-threatening disease. However, autoimmune reactions against CNS structures are could potentially be far more harmful. A possible solution to this problem might be to primarily focus on mutated peptides. By performing whole genome sequencing of tumor tissue and normal DNA samples, peptides spanning mutated sequences can be defined. As they should only be present on the surface of tumor cells and not on normal tissue, the risk for severe autoimmune reactions and collateral damage is reduced.
Furthermore, the tumor antigen should ideally be expressed on strategically important cell subpopulations such as glioma stem cells (GSCs), which play an essential role in tumor biology. 94, 95 GSCs represent only a small fraction of the total tumor burden, but these cells are believed to be resistant to chemo-and radiotherapy. Their tumor-initiating capacity is linked to glioblastoma recurrence after cytotoxic treatment. and CD4+ T helper cell interaction is mandatory for efficient anti-tumor immunity, e.g. by escaping activation-induced CTL cell death or supporting the formation of long-term memory. 103, 104 Although the role of CD4+ T helper cells is being discussed controversially, 105 we assume that a vaccinating agent should include tumor-associated peptides, which can bind to HLA class II molecules and promote a tumor-specific involvement of CD4+ T helper cells.
In summary, by analyzing the patient-individual HLA ligandome of freshly resected glioblastoma specimen in contrast to in vitro or in silico prediction of epitopes, it can be ascertained that a selected candidate peptide is actually naturally presented by the tumor in vivo. Whole genome sequencing of tumor and normal DNA allows identification of tumorspecific mutated peptides, thereby reducing the risk of autoimmunity. The aim should be to immunize not only with one, but with a cocktail of peptides adapted to the patient`s HLA haplotype and to the tumor individual mutations in order to reduce the chance of tumor escape. This personalized approach is promising but poses substantial logistical and technical challenges.
Suggestions for a peptide-based treatment protocol
Trying to meet all requirements and challenges of the above described antigen selection for a successful application of peptide-based immunotherapy against glioblastoma, we suggest the following protocol, which is depicted in Figure 3 . Directly after initial radiological diagnosis and strong suspicion for a malignant primary brain tumor such as glioblastoma, the required steps for a patient-specific treatment protocol have to be initiated.
Together samples should be collected and immune response should be monitored to determine T cell expansion as well as the optimal time point for re-boosting with the patient-suited multi peptide vaccine. The above strategy is in our mind an ideal one, however, as stated before, it is logistically very challenging in its implementation and costly.
SUMMARY, OUTLOOK AND FUTURE CHALLENGES
In this review we discussed challenges for peptide vaccination protocols in glioblastoma. One of the most important issues to be overcome is the tumor heterogeneity at a molecular and cellular level, which is presumably driven by GSCs along with a naturally transforming cell population and maintained by the high prevalence of new mutations within a fast growing tumor. This inter-and even intra-individual heterogeneity complicates the selection of appropriate targets for vaccination and thereby also the development of "off-theshelf" approaches. Therefore, patient-individual treatment protocols are needed.
Immunosuppressive properties of glioblastoma are mainly the result of cooperating processes of selection and mutation, which is summarized under the term immunoediting. 41 Due to the large variety of pathways employed by the tumor to evade, suppress and manipulate the immune system, especially in the local tumor environment, peptide vaccination strategies have to find appropriate ways to circumvent immunosuppresion to be able to translate into clinical success. Since murine studies have produced encouraging results of long-term immunity, 106 the goal of clinical immunotherapy has to remain achieving complete tumor regression. The following strategies represent options to overcome the abovementioned hurdles and pave the way to successful immunotherapy in glioblastoma.
To counteract heterogeneity and circumvent tumor-induced suppression of antigenspecific T cell responses, tumor vaccines should consist of multiple peptides that ideally should elicit efficient CD4+ and CD8+ T cell responses. Targeting multiple tumor-associated antigens will enhance the magnitude of immune response and decrease the chance of tumor escape by positive clonal selection of antigen-loss variants. 90 As described above, given the increasing evidence for a central role of GSCs in glioblastoma, a multi-peptide vaccine should also target stem cell-associated antigens in order to eliminate potential sources for recurrences. One future challenge will be the development of a GSC-targeting immunotherapy that avoids an autoimmune response against normal adult neural stem/progenitor cells. 96 These cells share a similar antigen profile with GSCs and potential and mediate an important role after chemo-and radiotherapy-induced tissue destruction.
They also have been proposed to inhibit glioblastoma growth by inducing cancer cell apoptosis. 107 Furthermore, to enhance anti-tumor efficacy, vaccines have to include peptides eluted from HLA class II for the purpose of eliciting a supportive CD4+ T cell expansion. Besides directly focusing on the presence of regulatory T cells, the inhibition of soluble factors, especially TGF- might facilitate improvement to an effective immune response. In that regard, a randomized study exploring the local delivery of TGF-β antisense oligonucleotides via catheter system confirmed the feasibility of this approach, but did not examine target inhibition and did not confirm its efficacy.
TGF-β pathway activation focus on small molecule inhibitors of Alk5, the major TGF-β receptor I, e.g., using LY2157299. The modality of peptide vaccines offers many additional therapeutic options besides targeting the tumor cells directly. Immunization with antigens exclusively expressed during angiogenesis could, for example, limit the supply of nutrition to the expanding tumor. 121, 122 Further, radio-and chemotherapy applies selective pressure on the tumor. This has been shown to result in mutations conferring properties of radio-and chemotherapy resistance to the tumor. The proteins mediating mechanisms of resistance now may result in new target antigens for immunotherapy, in the sense that peptide vaccines could not only constitute as an independent treatment approach, 123 but also serve as a synergistic tool supporting other treatment modalities. Individualized peptide-vaccination is therefore not only able to target patient-specific mutations and cell subpopulations, but also has the potential to be combined with other treatment modalities such as radio-and chemotherapy and represents an optimal complementation to neurosurgical treatment. Since immunotherapy is unlikely to be able to eradicate a large established tumor burden by itself, it is depending, at least for now, on neurosurgical resection for both tissue sampling and reduction of tumor load.
CONCLUSION
The heterogeneity and the transforming nature of glioblastoma as well as tumorassociated immunosuppression and immune evasion mechanisms pose a major challenge to treating physicians. Since conventional treatment options such as surgery, radio-and chemotherapy failed to profoundly improve overall survival; new treatment modalities are desperately needed. Immunotherapy offers high specificity and appears to be one of the most promising targeted approaches. We suggest a protocol to define tumor-associated antigens for peptide-based immunotherapy. Key elements of our approach are patientindividual screening for antigens, the use of multiple peptides covering all HLA alleles of the patient, the inclusion of both HLA class I and -II peptides, the focus on tumor-specific mutated peptides, and the definition of HLA ligands eluted from GSCs. Suitable antigenic peptides can then be used for peptide vaccination, but also for the loading of dendritic cells or for priming CTLs prior to an adoptive transfer to the patient. An international, randomized, double-blind, controlled study of Rindopepimut/GM-CSF with adjuvant Temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma (ACT IV).
Experimental: Rindopepimut /GM-CSF plus Temozolomide Active Comparator: KLH plus Temozolomide Each: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.
